Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion
XJTU1AF2025LSYY-461
Phase 1 small_molecule active
Quick answer
Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion for Diffuse Large B Cell Lymphoma (DLBCL) is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Diffuse Large B Cell Lymphoma (DLBCL)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active